WO2005105807A1 - 五環性タキサンの製造方法 - Google Patents
五環性タキサンの製造方法 Download PDFInfo
- Publication number
- WO2005105807A1 WO2005105807A1 PCT/JP2005/008034 JP2005008034W WO2005105807A1 WO 2005105807 A1 WO2005105807 A1 WO 2005105807A1 JP 2005008034 W JP2005008034 W JP 2005008034W WO 2005105807 A1 WO2005105807 A1 WO 2005105807A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- general formula
- compound represented
- boc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a method for producing an orally administrable taxane derivative having antitumor activity, particularly a pentacyclic taxane.
- Taxane derivatives are known as compounds having antitumor activity (Patent Documents 1 to 3).
- Patent Documents 2 and 3 describe a method for synthesizing an orally administrable taxane derivative and a powerful orally administrable taxane derivative.
- Patent Documents 2 and 3 disclose a method for synthesizing a taxane derivative using osmium tetroxide for the intermediate oxidation reaction (the following synthesis method 1 and synthesis method 2: wherein R 1 is a dimethylaminomethyl group or morpholinomethyl).
- R 2 represents a hydrogen atom, a halogen atom or an alkoxy group having 1 to 6 carbon atoms, and
- R 3 represents a hydroxyl group which may have a protecting group).
- Patent document 2 WOOlZ27115
- Patent Document 3 Japanese Patent Application Laid-Open No. 2002-332287
- an object of the present invention is to avoid the use of osmium tetraacid, use a low-toxicity and low-cost raw material, and provide a highly efficient and inexpensive taxi used as an orally administrable antitumor conjugate. It is intended to provide a method for producing a sun derivative.
- the present inventors have developed a method for obtaining a taxane derivative having a diol group by allowing an alkali metal permanganate to act on a taxane derivative having a terminal olefin.
- alkali metal permanganate having a strong oxidizing power is allowed to act on a compound having a complex structure, it is considered that decomposition will be caused and the efficiency of production on an industrial scale will decrease.
- this method it is possible to suppress the decomposition of the taxane derivative having a terminal olefin and obtain a taxane derivative having a diol group with high efficiency.
- the present inventors have developed a method for efficiently obtaining a taxane derivative by reducing the amount of a solvent relative to a reaction substrate. Further, according to this method, the purification operation is easy and the number of times of purification is small, so that the loss of the product in the purification step can be reduced, and the yield of the product is also improved. Therefore, the method of the present invention can obtain a product with high efficiency. Furthermore, alkali metal permanganates are more inexpensive than osmium tetraoxide and can be produced at lower cost, which is advantageous. That is, the present invention provides the following general formula (1)
- boc means a tert-butoxycarbol group
- Ac means an acetyl group
- Bz means a benzoyl group.
- R 1 represents an alkyl group, an alkyl group, an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group;
- the alkynyl group, cycloalkyl group, aryl group or heterocyclic group includes a halogen atom, a hydroxyl group, a carboxyl group, an alkyl group, an alkoxy group, a phenyl group, an amino group, an alkylamino group, an aminoalkyl group, and an alkylaminoalkyl group.
- Groups, alkoxycarbyl groups, aryloxycarbyl groups, acyl groups, acylamino groups and acyloxy groups may also have one or more substituents selected as the substituent.
- R 2 represents a hydroxyl group which may have a protecting group.
- alkali metal permanganate is allowed to act on the compound represented by the following general formula (2):
- the diol group of the taxane derivative represented by the general formula (2) obtained by the above-described production method is converted into a desired substituent according to a conventionally known method, and further, if necessary, the 6-position carbon By converting to a single bond when the bond between C and the carbon at position 7 is a double bond, and removing the protecting group when Z or R 2 is a hydroxyl group having a protecting group.
- a taxane derivative having an antitumor effect can be easily obtained. That is, the present invention further provides:
- boc means a tert-butoxycarbol group
- Ac means an acetyl group
- Bz means a benzoyl group.
- R 1 represents an alkyl group, an alkenyl group, an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group; these alkyl groups, alkenyl groups, alkynyl groups, cycloalkyl groups, aryl groups or heterocyclic groups
- the ring group includes a halogen atom, a hydroxyl group, a carboxyl group, an alkyl group, an alkoxy group, a phenol group, an amino group, an alkylamino group, an aminoalkyl group, an alkylaminoalkyl group, an alkoxycarbyl group, and an aryloxycarboxy group.
- An acyl group, an acylamino group, and an acyloxy group may have one or more groups selected as substituents.
- R 2 represents a hydroxyl group which may have a protecting group. )
- the alkyl group, alkenyl group, alkyl group, aryl group or heterocyclic group is an alkoxy group, an amino group, Alkylamino group, aminoalkyl group, alkylaminoalkyl group, cycloalkylamino group and the following formula (3-a)
- X represents an oxygen atom, a sulfur atom, CH, CH—Y, NH or N—Y
- a 5- or 6-membered saturated heterocyclic group containing a nitrogen atom represented by the formula (The heterocyclic group has one or more alkyl groups on a carbon atom that is a constituent atom of the ring. ) The group may have one or more groups selected as substituents. ⁇
- the target taxane derivative represented by the general formula (3) is
- boc represents a tert-butoxycarbyl group
- Ac represents an acetyl group
- Bz represents a benzoyl group.
- R 4 represents a halogen atom or an alkoxy group
- n represents 0 to 4 When n is 2 or more, two or more R 4 may be the same or different.
- R 6 represents a dimethylaminomethyl group or a morpholinomethyl group.
- the present invention further relates to a method for producing a taxane derivative which is easy to purify, highly efficient and inexpensive, as shown in the following items (i) to (iv).
- boc means a tert-butoxycarbol group
- Ac means an acetyl group
- Bz means a benzoyl group.
- R 4 represents a halogen atom or an alkoxy group
- n is an integer of 0 to 4. When n is 2 or more, two or more R 4 may be the same or different.
- R 5 It means a hydroxyl group which may have a protecting group.
- boc means a tert-butoxycarbol group
- Ac means an acetyl group
- Bz means a benzoyl group.
- R 4 represents a halogen atom or an alkoxy group
- n is an integer of 0 to 4. When n is 2 or more, two or more R 4 may be the same or different.
- R 5 represents a hydroxyl group which may have a protecting group.
- the method comprises the step of removing the protecting group: [0043] [Formula 19]
- R 4 means a dimethylaminomethyl group or a morpholinomethyl group.
- boc represents a tert-butoxycarbyl group
- Ac represents an acetyl group
- Bz represents a benzoyl group
- TIPS represents a triisopropylsilyl group.
- potassium permanganate is allowed to act on the compound represented by the following formula in a hydrous pyridine, or in a hydrous pyridine in the presence of lithium hydroxide.
- boc represents a tert-butoxycarbyl group
- Ac represents an acetyl group
- Bz represents a benzoyl group
- TIPS represents a triisopropylsilyl group.
- the present invention provides a novel intermediate (a compound represented by the general formula (12)) for obtaining a compound represented by the following general formula (16), and a compound represented by the general formula (16)
- the present invention relates to a method for producing a compound represented by the formula: That is, the present invention provides the following general formula (12) [0062] [Formula 27]
- R 7 represents a halogen atom or an alkoxy group, and n is an integer of 0 to 4.
- R 7 When n is 2 or more, two or more R 7 may be the same or different.
- R 8 represents an alkyl group, an aryl group or an alkoxy group, and the alkyl group, aryl group or alkoxy group represents a halogen atom, a hydroxyl group, a carboxyl group, an alkyl group, an alkoxy group, a phenyl group, an amino group, an alkylamino group; Group, aminoalkyl group, alkylaminoalkyl group, alkoxycarbyl group, aryloxycarbol group, acyl group, acylamino group, and acyloxy group. You may have more than one.
- R 9 represents a hydroxyl group which may have a protecting group.
- R 1C> represents an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group or a heterocyclic group, and these alkyl groups, alkaryl groups, alkyl groups, cycloalkyl groups, aryl groups Or a heterocyclic group includes a halogen atom, a hydroxyl group, a carboxyl group, an alkyl group, an alkoxy group, a phenol group, an amino group, an alkylamino group, an aminoalkyl group, an alkylaminoalkyl group, an alkoxycarbon group, A group consisting of a lyloxycarbyl group, an acyl group, an acylamino group and an acyloxy group.
- the compound may have one or more substituents as the substituent. )
- R 7 , R 8 , R 9 , n, Ac, and Bz are as defined above.
- the novel compound represented by the above general formula (12) is preferably a compound represented by the following general formula (13) [0071]
- R represents a halogen atom or an alkoxy group
- n is an integer of 0 to 4.
- R 11 represents an alkyl group, an aryl group or an alkoxy group, and the alkyl group, aryl group or alkoxy group represents a halogen atom, a hydroxyl group, a carboxyl group, an alkyl group, an alkoxy group.
- R 13 represents a hydroxyl group which may have a protecting group.
- R 14 represents a halogen atom, a pyrimidyl group, a nitrile group, an acyl group, or a methoxy group, and m is an integer of 0 to 5. When m is 2 or more, two or more R 14 may be the same or different.
- boc means a tert-butoxycarbol group
- TIPS means a triisopropylsilyl group.
- the present invention provides a compound represented by the above general formula (13),
- the compound represented by the above general formula (14) is more preferably converted to a compound represented by the following formula (19); [0081]
- the compound represented by the general formula (7) obtained by using the novel compound represented by the general formula (14) is a preferred embodiment of the taxane derivative aimed at by the present invention. It can be used for producing a compound represented by the above general formula (11). Therefore, the present invention further relates to a method for producing the compound represented by the general formula (13), using the novel conjugate represented by the general formula (14).
- the present invention further provides a compound represented by the general formula (7) by reacting the compound represented by the general formula (14) with a compound represented by the general formula (19).
- the compound represented by the above general formula (8) is produced by reacting potassium permanganate with the compound represented by the above general formula (7) in hydrous pyridine or in the presence of lithium hydroxide in hydrous pyridine.
- a compound represented by the above general formula (8) After reacting with the lithium metal periodate and then reacting with sodium acetoborohydride in the presence of acetic acid and dimethylamine, the above formula (9) is obtained, and then represented by the formula (9).
- a compound represented by the above general formula (10) by treating the compound with a nodium carbon catalyst in the presence of hydrogen gas, followed by the action of an ammonium fluoride salt.
- the present invention relates to a method for producing the compound represented by (11), a salt thereof, a hydrate or a solvate thereof.
- a taxane derivative having an antitumor effect can be easily purified, highly efficiently and inexpensively produced using a low-toxicity and inexpensive raw material, which is suitable for production on an industrial scale. It is.
- alkyl group may be straight or branched and may have 1 carbon atom (in the case of an alkyl group and an alkynyl group, Carbon number 2) Power Those with up to 6 carbon atoms are preferred.
- the "alkoxy group” means a group in which an alkyl group is bonded to a group O 2.
- the alkenyl group may be substituted with a phenyl group (which may have a substituent).
- a phenyl group which may have a substituent.
- Such examples include a benzyloxy group, a phenethyloxy group, a p-methoxybenzyloxy group and the like.
- the alkyl moiety preferably has 1 to 6 carbon atoms.
- alkoxycarbol group refers to a group in which an alkyl group is bonded to an oxygen atom of group COO, and the alkyl group is substituted with a phenyl group (which may have a substituent).
- a benzyloxycarbol group a phenethyloxycarbonyl group, a p-methoxybenzyloxycarbol group, and the like.
- the alkyl moiety preferably has 1 to 6 carbon atoms.
- aryl group means a monovalent group obtained by removing one hydrogen atom from the aromatic hydrocarbon, such as a phenyl group, a tolyl group, a biphenyl group, and a naphthyl group. And the like.
- the bonding position of the amino group of the "aminoalkyl group” may be any position of the alkyl group.
- the alkyl group preferably has 1 to 6 carbon atoms.
- alkylamino group refers to an amino group substituted with one alkyl group or an amino group substituted with two alkyl groups (the two alkyl groups may be the same or different).
- the alkyl group preferably has 1 to 6 carbon atoms.
- acyl group refers to a group in which a hydrogen atom, an alkyl group, or an aryl group is bonded to a carboxyl group (one CO—), for example, a formyl group, an acetyl group, a propanol group, or a benzoyl group. And the like.
- the alkyl group to be bonded preferably has 1 to 6 carbon atoms, and the aryl group to be bonded is preferably a phenyl group.
- heterocyclic group refers to a monocyclic or bicyclic group containing one or more atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom as constituent atoms of a ring structure.
- Cyclic saturated or unsaturated heterocyclic compound means a substituent derived, and these heterocyclic groups may be bonded at any position.
- Monocyclic heterocyclic groups include, for example, pyrrole, furan, thiophene, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, imidazole, pyrazole, imidazolidine, virazolidine, oxazole, thiazole, oxazidazole, thiadiazole, pyridine, Monocyclic heterocyclic compounds such as dihydropyridine, tetrahydropyran, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, dioxane, pyran, and morpholine.
- bicyclic heterocyclic group examples include substituents derived from a bicyclic heterocyclic compound such as benzofuran, indolizine, benzothiophene, indole, naphthyridine, quinoxaline, quinazoline, and chroman.
- X is an oxygen atom, a sulfur atom, CH
- ⁇ means an alkyl group.
- a 5- to 6-membered saturated heterocyclic group containing a nitrogen atom. The heterocyclic group has one alkyl group on the carbon atom that constitutes the ring.) Or more than one.
- R 1 in the general formula (1) is preferably an aryl group, a heterocyclic group, or an alkenyl group.
- the “aryl group” of R 1 is preferably a feather group, and the “alkenyl group” is preferably a 2-methyl-1 probel group.
- a monocyclic heterocyclic group is preferable, and further, a monocyclic 5- or 6-membered heterocyclic group is preferable, for example, pyrrole, furan, Thiophene, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, imidazole, pyrazole, imidazolidine, virazolidine, oxazole, thiazole, oxadiazole, thiadiazole, pyridine, dihydropyridine, tetrahydropyran, piberidine, pyridazine, pyrimidine, pyrazine, pyrazine, dioxane And substituents derived from pyran and morpholine.
- heterocyclic groups of R 1 are monocyclic 5- or 6-membered oxygen atom as a constituent atom of the heterocyclic group ring ring nitrogen atom or a sulfur atom especially one containing heterocyclic group a good
- examples of such groups include pyrrole, furan, thiophene, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, pyridine, dihydropyridine, tetrahydrosilane, piperidine, and pyran.
- a monocyclic 5- or 6-membered heterocyclic group is most preferably an unsaturated heterocyclic group containing one oxygen atom, nitrogen atom or sulfur atom as a constituent atom of the ring structure, Specifically, a group derived from furan, pyridine and pyrrolca is most preferred.
- R 1 is particularly preferably a 2-methyl-1-probe group, a phenyl group, a furyl group, a pyridyl group or a pyrrolyl group, particularly a halogen atom (preferably a fluorine atom) or an alkoxyl group. And a pyridyl group, which is substituted with a group.
- R 2 denotes a hydroxyl group which may have a protecting group.
- the protecting group for R 2 include a substituted silyl group, a benzyl group, a substituted benzyl group, a 1-ethoxyshethyl group, a benzyloxycarbyl group, and a 2,2,2-trichloromouth ethoxycarbyl group. I can do it.
- Examples of the substituent of the substituted silyl group include an alkyl group, an aryl group and an aralkyl group.
- Examples of the substituted silyl group include a trimethylsilyl group, an isopropyldimethylsilyl group, a tertiary butyldimethylsilyl group, a tribenzylsilyl group, and a t-benzylsilyl group.
- Examples of the substituent of the substituted benzyl group include a halogen atom, an alkyl group, an alkoxy group, and a nitro group.
- Examples of the substituted benzyl group include a no-trobenzyl group and a noramethoxybenzyl group.
- the protecting group for R 3 is preferably a triisopropylsilyl group, a tertiary butyldimethylsilyl group, a triethylsilyl group, or the like. Examples thereof include a trialkylsilyl group and a benzyl group, and particularly preferably a triisopropylsilyl group and a benzyl group.
- the compound represented by the general formula (1) is more preferably a compound represented by the above general formula (4), and particularly preferably a compound represented by the general formula (7).
- the alkyl group is preferably tool especially a methyl group those having 1 to 6 carbon atoms, Echiru group, preferably a propyl group instrument Aruke - The group, carbon atoms Particularly preferred is an aryl group of 2-6.
- a 5- or 6-membered saturated heterocyclic group containing a nitrogen atom (the heterocyclic group may have an alkyl group on a carbon atom as a constituent atom of the ring) Is preferred.
- the alkyl moiety of the alkylamino group is preferably a dialkyl
- the two alkyl groups may be the same or different! /).
- a saturated heterocyclic group having the size of a 5- or 6-membered ring containing a nitrogen atom and represented by the above formula (3-a) (the heterocyclic group is a constituent atom of the ring). May have one or more alkyl groups on the carbon atom). Among them, piperazine, morpholine, thiomorpholine, and a group from which a 4-C to C alkylpiperazine force is also derived are particularly preferable. Also, a heterocyclic group
- a methyl group is preferable.
- R 3 and more preferably a dimethyl ⁇ amino methyl or morpholinomethyl group, preferably in particular, dimethyl ⁇ amino methyl.
- the compound represented by the general formula (3) is more preferably a compound represented by the general formula (6).
- the present invention provides a compound represented by the above general formula (2) by reacting a compound represented by the above general formula (1) with an alkali metal permanganate. To produce a salt, a hydrate thereof, or a solvate thereof (hereinafter, also referred to as step (b)) And features.
- Examples of the "alkali metal permanganate” used in the present invention include sodium permanganate, potassium permanganate, and cesium permanganate. Preferred is potassium permanganate.
- the molar ratio of the “compound represented by the general formula (1)” to the “alkali metal permanganate” is typically 1: 0.5 to 1: 2, preferably 1: 1 to 1: 1. .5.
- the base is not particularly limited, and pyridine, potassium carbonate, triethylamine, sodium hydroxide, lithium hydroxide, aqueous ammonia, and the like can be used. Preferred are pyridine, lithium hydroxide, sodium hydroxide and aqueous ammonia, and more preferred are pyridine and lithium hydroxide.
- the molar ratio of the “compound represented by the general formula (1)” to the “base” is typically 1: 0.1 to 1: 1, preferably 1: 0.2 to 1: 0.8. .
- the solvent is not particularly limited as long as it is inert to the reaction, and ether solvents such as hydrous tetrahydrofuran, hydrous 1,4 dioxane, hydrous dimethoxyethane, etc., hydrous acetonitrile, hydrous pyridine, hydrous acetone Etc. can be used. Of these solvents, hydrous tetrahydrofuran, hydrous acetone or hydrous pyridine are preferred. More preferably, it is a hydrous pyridine.
- the water content is typically 10-40%, preferably 20-40%, more preferably 20-35%.
- water-containing used for water-containing pyridine, water-containing tetrahydrofuran, water-containing acetone, or water-containing solvent includes, for example, pyridine, tetrahydrofuran, acetone or other kinds of solvents and water during the reaction. Means that. Mixing of water with pyridine, tetrahydrofuran, acetone or another type of solvent may be performed before the reaction with the other compound, or simultaneously with the reaction with the other compound, They may be mixed during the reaction.
- the solvent may be of a different type or the same type as the above base.
- hydrous pyridine which is preferred by pyridine, is more preferable.
- the reaction temperature is generally in the range of 0 ° C to the boiling point of the solvent, preferably in the range of 20 ° C and the boiling point of the solvent, and more preferably in the range of 30 ° C to 50 ° C.
- the reaction time is generally about 5 minutes to 2 hours, preferably 15 minutes to 1 hour.
- the amount of the solvent relative to the reaction substrate is also an important consideration.
- the production efficiency improves as the amount of the solvent relative to the reaction substrate decreases.
- the amount of the solvent for the reaction substrate is preferably about 10 to 50 times, more preferably about 10 to 50 times.
- the amount is 15 to 40 times, more preferably 15 to 30 times.
- the compound represented by the general formula (1) of the present invention can be produced, for example, by the method described in JP-A-9-12578.
- the compound represented by the general formula (2) obtained according to the present invention can be obtained by a conventionally known method.
- step (c) The CH (OH) CH OH group is converted to the above —R 3 group (hereinafter also referred to as step (c)), and if necessary,
- step (d) when the bond between carbons 6 and 7 is a double bond, the reaction is converted to a single bond (hereinafter, also referred to as step (d)), and Z or R 2 has a protecting group.
- the compound represented by the above general formula (3) can be obtained by performing a reaction for removing the protecting group in the case of a hydroxyl group (hereinafter, also referred to as step (e)).
- an acid such as acetic acid and a reducing agent such as sodium acetoborohydride.
- the R 3 group is a dimethylaminomethyl group
- the source of the dimethylamino group is more preferably dimethylamine methanol solution or dimethylamine hydrochloride, which is more preferable!
- Examples of the alkali metal periodate that can be used in step (c) include lithium periodate, sodium periodate, and potassium periodate. Preferred is sodium periodate.
- the amount of the alkali metal periodate used is calculated based on the number of moles of the compound represented by the general formula (1) used in the above step (b), and the amount of the compound represented by the general formula (1)
- the molar ratio of "" to "alkali metal periodate” is typically 1: 1 to 1: 4, preferably 1: 1 to 1: 3, particularly preferably 1: 2.
- the solvent used when the alkali metal periodate is allowed to act on the compound represented by the general formula (2) is not particularly limited as long as it is inert to the reaction.
- Ether solvents such as dioxane and hydrated dimethoxyethane
- alcoholic solvents such as hydrated methanol, hydrated ethanol and hydrated 2-propanol
- hydrated acetonitrile hydrated pyridine
- hydrated acetone and dimethylformamide can be used.
- hydrous acetonitrile is preferred.
- the water content is typically 10-90%, preferably
- the base may or may not be added, but it is preferable to add the base.
- the base to be added is not particularly limited, and pyridine, potassium carbonate, sodium bicarbonate, triethylamine, sodium hydroxide, etc.
- pyridine is used.
- the temperature is usually in the range of 0 ° C to the boiling point of the solvent, preferably in the range of 20 ° C to 50 ° C.
- the reaction is for about 30 minutes to 24 hours, typically 2 hours to 18 hours.
- the amount of the acid such as acetic acid used is calculated based on the number of moles of the compound represented by the general formula (1) used in the step (b),
- the molar ratio of "" to "acid” is typically 1: 0
- the amount of R (for example, dimethylamine) used is calculated based on the number of moles of the compound represented by the general formula (1) used in the step (b),
- the molar ratio of R to R is typically from 1: 0.5 to 1: 4, preferably from 1: 1 to 1: 2, particularly preferably 1: 1.5.
- the amount of the reducing agent such as sodium acetoborohydride used is calculated based on the number of moles of the compound represented by the general formula (1) used in the step (b), Is typically 1: 1 to 1: 6, preferably 1: 2 to 1: 4, and particularly preferably 1: 2. 3
- the solvent used when the reducing agent is allowed to act on the compound represented by the general formula (2) is not particularly limited as long as it is inert to the reaction, and ether solvents such as tetrahydrofuran, 1,4-dioxane, and dimethoxyethane may be used.
- ether solvents such as tetrahydrofuran, 1,4-dioxane, and dimethoxyethane may be used.
- Acetate-based solvents such as methyl acetate and ethyl acetate, and other acetonitrile, pyridine, dimethylformamide and the like can be used. Of these solvents, tetrahydrofuran and ethyl acetate are preferred.
- the reaction temperature when the reducing agent is allowed to act on the compound represented by the general formula (2) is usually in the range of 78 ° C to the boiling point of the solvent, and preferably in the range of 0 ° C to the boiling point of the solvent. , Most preferably in the range of 0 ° C to 30 ° C.
- the reaction time when the reducing agent is allowed to act on the compound represented by the general formula (2) is about 30 minutes to 5 hours, typically 1 hour to 3 hours.
- step (d) for converting the bond between the carbon at position 6 and the carbon at position 7 to a single bond when the bond is a double bond is specifically obtained in the above step (c). It can be carried out by treating the mixed product with a reducing catalyst such as palladium carbon, platinum carbon or ruthenium carbon in the presence of hydrogen gas.
- a reducing catalyst such as palladium carbon, platinum carbon or ruthenium carbon in the presence of hydrogen gas.
- step (d) hydrogen gas, formic acid, and ammonium formate can be used, and preferably ammonium formate. These sources of hydrogen continue to be supplied until the reaction is virtually complete.
- the amount of the catalyst such as palladium carbon used is calculated based on the weight of the compound represented by the general formula (1) used in the step (b), and the “compound represented by the general formula (1)” and “
- the weight ratio of ⁇ a catalyst such as palladium carbon catalyst '' is typically 1: 0.05 to 1: 1, preferably 1: 0.1 to 1: 0.5, particularly preferably 1: 0.25 Is advantageous.
- the solvent is not particularly limited and includes alcohol solvents such as methanol, ethanol and 2-propanol, ether solvents such as tetrahydrofuran, 1,4-dioxane and dimethoxyethane, and acetate esters such as methyl acetate and ethyl acetate.
- alcohol solvents such as methanol, ethanol and 2-propanol
- ether solvents such as tetrahydrofuran, 1,4-dioxane and dimethoxyethane
- acetate esters such as methyl acetate and ethyl acetate.
- a system solvent, acetonitrile, pyridine, dimethylformamide and the like can be used. Of these solvents, ethanol is preferred.
- Typical moisture content is 0-50%, preferably 0-25%.
- the reaction temperature varies depending on the solvent used.
- the reaction temperature is generally in the range of 0 ° C to the boiling point of the solvent, preferably in the range of 20 ° C and 60 ° C.
- the reaction time ranges from about 1 hour to 3 days and continues until the reaction is substantially complete.
- step (e) When R 2 is a hydroxyl group having a protecting group, the reaction for removing the protecting group (step (e)) is carried out under different deprotection conditions depending on the type of the protecting group. Deprotection can be achieved by allowing an ammonium fluoride salt to act on the compound obtained in (b) or the step (c).
- the ammonium fluoride salt used in step (e) is not particularly limited. Trabutylammonium is preferred.
- the amount of the ammonium fluoride salt to be used is calculated based on the number of moles of the compound represented by the general formula (1) used in the step (b), and is calculated as “the compound represented by the general formula (1)”.
- the molar ratio of the “ammonia fluoride salt” to “ammonia fluoride salt” is typically 1: 0.5 to 1:10, but is not particularly limited, and is continuously supplied until the reaction is substantially completed.
- the solvent is not particularly limited as long as it is inert to the reaction, and ether solvents such as tetrahydrofuran, 1,4-dioxane, and dimethoxyethane; acetate solvents such as methyl acetate and ethyl acetate; , Ethanol, 2-propanol and other alcohol solvents, acetonitrile, pyridine, dimethylformamide and the like. Of these solvents, ethyl acetate is preferred.
- the reaction temperature varies depending on the solvent used, but it is usually in the range of 0 ° C to the boiling point of the solvent, preferably 20 ° C.
- the taxane derivative represented by the general formula (3) obtained by the present invention can be isolated by recrystallization after treating the reaction solution.
- the solvent is not particularly limited, but alcoholic solvents such as hydrated methanol, hydrated ethanol, and hydrated 2-propanol; ethereal solvents such as hydrated tetrahydrofuran, hydrated 1,4-dioxane, and hydrated dimethoxyethane; and other hydrated acetone. Hydrated acetonitrile, hydrated N, N-dimethylformamide and the like can be used. Of these solvents, aqueous acetone is preferred.
- the water content in the solvent is in the range of 10 to 90%, preferably 20 to 60%, particularly preferably 20 to 40%.
- the present invention provides a compound represented by the general formula (3) that is finally obtained,
- the compound represented by the formula (6) is preferred, and the compound represented by the general formula (11) is particularly preferred.
- the present invention provides a compound represented by the formula (8) obtained by reacting a compound represented by the formula (7) with an alkali metal permanganate in the presence of a base. A compound is produced (step (b)).
- step (b) a compound represented by the formula (8) is obtained, and alkali metal periodate is allowed to act on compound (8), followed by hydrogenation in the presence of acetic acid and dimethylamine.
- the compound represented by the formula (9) is obtained by reacting sodium acetoborohydride (step (c)), and if necessary, the compound (9) is treated with a hydrogen-carbon catalyst in the presence of hydrogen gas.
- the compound is reduced to the compound represented by the formula (10) (step (d)), and then, if necessary, deprotection is carried out by the action of a Futirimi-ammonium salt (step (e)).
- a Futirimi-ammonium salt step (e)
- step (e) To produce the compound represented by the formula (11) or a salt thereof.
- boc is tert- flop Toki deer Lupo sulfonyl group
- TIPS means triisopropoxide building silyl group
- a c is Asechiru group
- B z is Benzoiru group.
- the compound (7) can also be obtained by the method described in JP-A-2002-332287, but as shown in the following step (a), a novel compound represented by the formula (14)
- the compound can also be produced by reacting the compound represented by the formula (19) with the compound.
- the novel compound (14) is a compound represented by the formula (20) ⁇ (3R, 4S) -11- (tert-butoxycarbol) 4- (3-fluoro1-2pyridyl) 3 triisopropylsilyloxy-l-azetidinone ⁇ with 4-bromothiophenol to form a thiol ester (also referred to as "thioesteridani" in this specification).
- Compound (20) is disclosed in It can be obtained by the method described in 2-332287.
- Compound (14) can be obtained by thioesterifying the above compound (20) with 4-bromothiophenol.
- Compound (14) can be obtained by reacting compound (20) with a compound having a thiol group according to a conventional method. Specifically, for example, the compound (14) can be obtained by reacting the compound (20) with a compound having a thiol group in an appropriate solvent in the presence of a base, if necessary.
- the compound having a thiol group include, but are not limited to, 4-bromobenzenethiol, 4-chlorobenzenethiol, and 2-mercaptoimidazole.
- Preferred examples of the compound having a thiol group include 4-bromobenzenethiol and 4-chlorobenzenethiol, more preferably 4-bromobenzenethiol.
- the thioesteridani reaction is preferably performed in the presence of a base.
- the base is not particularly limited and includes amines such as 4- (dimethylamino) pyridine, triethylamine, N, N-pyridine, and alkali or alkaline earth metal salts such as potassium carbonate, sodium carbonate, cesium carbonate, and calcium carbonate.
- the available force is preferably potassium carbonate.
- the weight ratio of the compound (20) to the base is typically 1: 0.001 to 1: 1, preferably 1: 0.1 to 1: 0. 3.
- Solvents are not particularly limited as long as they are inert to the reaction, and ether solvents such as diisopropyl ether, getinoleatenole, tetrahydrofuran, 1,4 dioxane and dimethoxyethane, and esters such as ethyl acetate and methyl acetate.
- Solvents, ketone solvents such as acetone and methyl isobutyl ketone, amide solvents such as N, N dimethylformamide and 1,3 dimethylimidazolidinone, hydrocarbon solvents such as n -heptane, n-hexane and cyclohexane Acetonitrile, pyridine, toluene and the like can be used.
- diisopropyl ether is preferred.
- the reaction temperature is generally in the range of 0 ° C to the boiling point of the solvent, preferably in the range of 15 ° C and the boiling point of the solvent.
- the reaction is for about 1 minute to 36 hours, typically 5 minutes to 3 hours.
- Another production method of compound (14) also includes a reaction in which the side chain of the carboxylic acid type taxane derivative is protected with an appropriate protecting group and then thioesterich is added with 4-bromothiophenol.
- a method for synthesizing a carboxylic acid type taxane derivative side chain is described, for example, in the following document [Org. Chem., 1991, 56, 6939-6942; Org. Chem., 1993, 58, 255]. -257; J. Org. Chem., 1994, 59, 1238-1240; Tetrahedr on Asymmetry, vol. 7, No. 1, 243-262, 1996; Tetrahedron Letters 44 (2003) 8685-8687.
- step (a) As a method for obtaining compound (7) from compound (14) (step (a)), compound (19) is reacted with compound (14) in a non-reactive solvent in the presence of a base. Compound (7) can be obtained. Compound (19) can be obtained by the method described in JP-A-2002-332287. The molar ratio of compound (19) to compound (14) is typically from 1: 1 to 1: 3, preferably 1: 1: 1.5.
- the base is not particularly limited, and is capable of using alkali metal hydrides such as sodium hydride, lithium hydride, and potassium hydride, and alkali metal amides such as lithium diisopropylamide.
- the base is sodium hydride. is there.
- the molar ratio of compound (19) to base is typically from 1: 1 to 1: 6, preferably Or 1: 2 to 1: 4.
- the solvent is not particularly limited as long as it is inert to the reaction, and ether solvents such as tetrahydrofuran, ethyl ether, 1,4-dioxane and dimethoxyethane, and other solvents such as acetate nitrile, ethyl acetate, dimethylformamide, and toluene are used. be able to. Of these solvents, dimethoxyethane is particularly preferred, with ether being preferred.
- the reaction temperature varies depending on the solvent used.
- the reaction temperature is usually 78 ° C.
- the reaction temperature is in the range of the boiling point of the solvent, preferably in the range of 0 ° C to 30 ° C.
- the reaction is continued for about 10 minutes to 10 hours, typically 1 hour to 5 hours, until substantially complete.
- This step is preferably performed in an atmosphere of an inert gas such as nitrogen or argon.
- Compound (7) can be isolated by recrystallization after treating the reaction solution.
- the solvent is not particularly limited, alcohol solvents such as methanol, ethanol and 2-propanol, ether solvents such as diisopropyl ether, etc., and acetonitrile, ethyl acetate, toluene and the like can be used. Of these solvents, ethanol is preferred.
- the purity of the recrystallized compound (7) can be further increased by slurry purification.
- the solvent hydrocarbon solvents such as hexane, heptane and cyclohexane and mixtures thereof, alcohol solvents such as methanol, ethanol and isopropanol, and diisopropyl ether, acetonitrile and the like can be used. Of these solvents, hexane-cyclohexane mixtures are preferred.
- step (a) The compound (7) obtained in the above step (a) can be further subjected to the steps (b) to (e) to give the compound (11). Steps (b) to (e) and the resulting method for purifying the compound represented by the formula (11) are as described above.
- the steps (a) to (e) can be performed on an industrial scale, and the target taxane derivative represented by the general formula (3) can be efficiently obtained. .
- the compound obtained in the present invention may be a free form! / ⁇ , or may be an acid addition salt! / ⁇ .
- the acid addition salt include inorganic salts such as hydrochloride, sulfate, nitrate, hydrogen bromide, hydrogen iodide, and phosphate, or acetate, methanesulfonate, benzenesulfonate, and toluenesulfonate.
- Organic salts such as acid, citrate, maleate, fumarate and lactate. You can.
- Examples of the solvent which may be a hydrate or a solvate include methanol, ethanol, propanol, butanol, acetone, acetonitrile, benzene, toluene, tetrahydrofuran, N, N-dimethylformamide and the like.
- the compound obtained in the present invention as a medicine, a cancer treatment based on an antitumor effect can be achieved, and the treatment target is lung cancer, gastrointestinal cancer, ovarian cancer, uterine cancer, breast cancer. And various cancers such as liver cancer, head and neck cancer, blood cancer, kidney cancer and testicular tumor.
- the compound obtained by the present invention can be administered as various injections such as intravenous injection, intramuscular injection, subcutaneous injection or the like, or by various methods such as oral administration and transdermal administration. Of these administration methods, oral administration is preferred from the viewpoint of achieving the effects described below. In the case of oral administration, either free form or salt is acceptable.
- an appropriate preparation is selected in accordance with an administration method, and can be prepared by a commonly used preparation method of various preparations.
- the preparation for oral administration among the dosage forms of the antitumor agent of the present invention include tablets, powders, granules, capsules and the like.
- the form of the preparation include a solution, a syrup, an elixir, an oily or aqueous suspension, and the like. Of these, capsules, tablets and solutions are preferred.
- stabilizers, preservatives, solubilizing agents and the like can be used in the preparation. Solutions that may contain these adjuvants can be used as solid preparations by freeze-drying or the like as preparations for use.
- liquid preparations examples include solutions, suspensions, and emulsions.
- suspending agents, emulsifiers, and the like can also be used as additives.
- the compound of the present invention can be used for treating cancer in mammals, especially humans. When administered to humans, it is preferably administered once a day and repeated at appropriate intervals.
- the dose is preferably in the range of about 0.5 mg to 50 mg, preferably about 1 mg to 20 mg, per lm 2 of the body surface area!
- Boc tert butoxycarbinole group
- reaction proceeded in a solvent or tetrahydrofuran (THF) solvent, but many impurities were generated.
- THF tetrahydrofuran
- the reaction proceeded in acetone or THF.
- Compound 7 was insoluble in acetonitrile.
- a reaction solvent other than the THF solvent or the acetone solvent used in Example 1 was examined.
- 11 types of solvents pyridine, acetylacetone, dimethoxyacetone, ether, piperidine, triethylamine, dimethylformamide, (Dimethylsulfoxide, acetic acid, acetic anhydride), it was found that the reaction proceeded favorably in a pyridine solvent.
- Table 2 shows the results. Area% in Table 2 is the ratio of each peak area to the sum of each peak area, calculated based on each peak area obtained by HPLC. It is.
- the amount of hydrous pyridine (volume) relative to compound 7 (weight) was varied while keeping the amount of solution (0.00995 mmol) constant.
- Table 4 shows the results.
- the area% in Table 4 is the ratio of each peak area to the sum of each peak area calculated based on each peak area obtained by HPLC.
- dimethoxyethane was added to 6.37 g of sodium hydride (content: 55%, 146 mmol), and the system was replaced with nitrogen gas.After cooling with ice water, it was dissolved in 204 mL of dimethoxyethane (IS, 2S, 3R, 4S, 5R, 8R, 9S, 10R, 13S)-4-Acetoxy-2-benzoyloxy-5,20-epoxy-1,13-dihydroxy-9,10-[(lS) -2-propylidenedoxy 25.5 g (44.9 mmol) of Tax-6,11-gen were added dropwise.
- dimethoxyethane IS, 2S, 3R, 4S, 5R, 8R, 9S, 10R, 13S
- Og (29.8 mmol) was mixed with 450 mL of pyridine and 25.9 mL of water, stirred at room temperature, and stirred at room temperature with 1.49 mL (5.96 mmol) of 4N lithium hydroxide aqueous solution. 122.6 mL (38.8 mmol) of a 50 g ZL aqueous potassium permanganate solution was added thereto, and the mixture was stirred for about 30 minutes.
- the concentrated solution was extracted with ethyl acetate, and the organic layer was separated and washed twice with a mixture of 2N hydrochloric acid and saturated saline, and then once with a mixture of 4% sodium bicarbonate and saturated saline.
- the organic layer was dried over magnesium sulfate, concentrated under reduced pressure, and the concentrated solution was treated with 300 mL of tetrahydrofuran, 1.70 mL (29.8 mmol) of acetic acid, and 22.4 mL (44.8 mmol) of a 2 mol ZL dimethylamine methanol solution. The mixture was stirred while cooling with ice water.
- reaction mixture was added to a mixture of 315 mL of a 4% aqueous sodium hydrogen carbonate solution and 350 mL of ethyl acetate under cooling with ice water, and 175 mL of saturated saline was further added for extraction and liquid separation.
- the organic layer was separated, washed with a mixed solution of 350 mL of water and 210 mL of saturated saline, and then with 315 mL of saturated saline, and then concentrated under reduced pressure.
- Ethanol (805 mL) was added to the concentrated residue, and the mixture was heated and dissolved at 50 ° C., inoculated, and stirred at room temperature overnight.
- the organic layer was separated, washed with a mixture of 120 mL of a 10% aqueous solution of citric acid and 120 mL of a saturated saline solution, and then washed with a mixed solution of 200 mL of a 4% aqueous sodium hydrogen carbonate solution and 120 mL of a saturated saline solution, and concentrated under reduced pressure.
- the concentrated solution was extracted with 400 mL of ethyl acetate and 80 mL of saturated saline, and the organic layer was separated.
- the organic layer was separated twice, twice with a mixture of 80 mL of 2N hydrochloric acid and 80 mL of saturated saline, and then with 160 mL of 4% sodium bicarbonate. It was washed once with a mixed solution of 160 mL of saturated saline.
- the organic layer is dried over magnesium sulfate, concentrated under reduced pressure to about 400 mL, 4.9 g (59.7 mmol) of dimethylamine hydrochloride and 4.9 g (59.7 mmol) of sodium acetate are added, and the mixture is stirred under ice-water cooling.
- the compound 11 is obtained from the compound 7 according to the method described in Example 6 of the present invention, and the method described in JP-A-2002-332287 is used to react the compound 7 with diol. Then, the difference in yield between the case where compound 11 was obtained from compound 7 and the case where compound 11 was obtained was compared. The results are shown in the table below. Similarly, in the method described in Example 7 or 8, the yield was improved as compared with the conventional method.
- the taxane derivative obtained by the production method of the present invention is useful as an orally administrable antitumor active compound.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005800117870A CN1942473B (zh) | 2004-04-30 | 2005-04-27 | 生产五环紫杉烷的方法 |
CA2565013A CA2565013C (en) | 2004-04-30 | 2005-04-27 | Method for producing pentacyclic taxans |
EP05737233A EP1741716B8 (en) | 2004-04-30 | 2005-04-27 | Process for producing pentacyclic taxane |
DK05737233.6T DK1741716T3 (da) | 2004-04-30 | 2005-04-27 | Fremgangsmåde til fremstilling af pentacyklisk taxan |
MXPA06012588A MXPA06012588A (es) | 2004-04-30 | 2005-04-27 | Proceso para producir taxano pentaciclico. |
US11/579,140 US7456302B2 (en) | 2004-04-30 | 2005-04-27 | Method for producing pentacyclic taxans |
AT05737233T ATE526332T1 (de) | 2004-04-30 | 2005-04-27 | Verfahren zur herstellung von pentacyclischem taxan |
KR1020067025289A KR101186475B1 (ko) | 2004-04-30 | 2005-04-27 | 펜타사이클릭 탁산의 제조방법 |
JP2006512820A JP4800205B2 (ja) | 2004-04-30 | 2005-04-27 | 五環性タキサンの製造方法 |
IL178918A IL178918A (en) | 2004-04-30 | 2006-10-29 | Process for producing pentacyclic taxane |
HK07101873.3A HK1094582A1 (en) | 2004-04-30 | 2007-02-15 | Process for producing pentacyclic taxane |
US12/238,070 US7678919B2 (en) | 2004-04-30 | 2008-09-25 | Method for producing pentacyclic taxans |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004136359 | 2004-04-30 | ||
JP2004-136359 | 2004-04-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/579,140 A-371-Of-International US7456302B2 (en) | 2004-04-30 | 2005-04-27 | Method for producing pentacyclic taxans |
US12/238,070 Division US7678919B2 (en) | 2004-04-30 | 2008-09-25 | Method for producing pentacyclic taxans |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005105807A1 true WO2005105807A1 (ja) | 2005-11-10 |
Family
ID=35241616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/008034 WO2005105807A1 (ja) | 2004-04-30 | 2005-04-27 | 五環性タキサンの製造方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US7456302B2 (ja) |
EP (1) | EP1741716B8 (ja) |
JP (1) | JP4800205B2 (ja) |
KR (1) | KR101186475B1 (ja) |
CN (1) | CN1942473B (ja) |
AT (1) | ATE526332T1 (ja) |
CA (1) | CA2565013C (ja) |
DK (1) | DK1741716T3 (ja) |
ES (1) | ES2371947T3 (ja) |
HK (1) | HK1094582A1 (ja) |
IL (1) | IL178918A (ja) |
MX (1) | MXPA06012588A (ja) |
PT (1) | PT1741716E (ja) |
WO (1) | WO2005105807A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100056770A1 (en) * | 2006-10-10 | 2010-03-04 | Axt Steven D | Preparation of nucleosides ribofuranosyl pyrimidines |
JP2013530234A (ja) * | 2010-06-30 | 2013-07-25 | ジェンタ インコーポレイテッド | テセタキセルおよび関連化合物ならびに対応する合成中間体の調製 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008121476A1 (en) * | 2007-03-28 | 2008-10-09 | Tapestry Pharmaceuticals, Inc. | Biologically active taxane analogs and methods of treatment by oral administration |
US8697892B2 (en) | 2010-06-30 | 2014-04-15 | Gfv, Llc | Taxane compounds, compositions and methods |
FR2986526A1 (fr) | 2012-02-03 | 2013-08-09 | Sanofi Sa | Procede de preparation de derives du taxol et certains composes intermediaires |
SG11201406885VA (en) * | 2012-04-25 | 2014-11-27 | Gfv Llc | Taxane compounds, compositions and methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0912578A (ja) * | 1995-04-28 | 1997-01-14 | Dai Ichi Seiyaku Co Ltd | 五環性化合物 |
WO2001027115A1 (fr) * | 1999-10-15 | 2001-04-19 | Daiichi Pharmaceutical Co., Ltd. | Composes pentacycliques au taxane |
JP2002332287A (ja) * | 2001-03-07 | 2002-11-22 | Dai Ichi Seiyaku Co Ltd | 五環性タキサン化合物およびその製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094940C (zh) * | 1995-04-28 | 2002-11-27 | 第一制药株式会社 | 具有抗肿瘤活性的紫杉酚衍生物 |
US6008417A (en) * | 1997-10-20 | 1999-12-28 | Roche Vitamins Inc. | Process for making metabolites of lycopene |
US6677456B2 (en) * | 1999-10-15 | 2004-01-13 | Daiichi Pharmaceutical Co., Ltd. | Pentacyclic taxan compound |
DE60224440T2 (de) | 2001-11-29 | 2009-01-02 | Daiichi Sankyo Co., Ltd. | Kristalle von taxanderivaten und verfahren zu deren herstellung |
-
2005
- 2005-04-27 AT AT05737233T patent/ATE526332T1/de active
- 2005-04-27 DK DK05737233.6T patent/DK1741716T3/da active
- 2005-04-27 US US11/579,140 patent/US7456302B2/en active Active
- 2005-04-27 EP EP05737233A patent/EP1741716B8/en not_active Not-in-force
- 2005-04-27 JP JP2006512820A patent/JP4800205B2/ja not_active Expired - Fee Related
- 2005-04-27 ES ES05737233T patent/ES2371947T3/es active Active
- 2005-04-27 KR KR1020067025289A patent/KR101186475B1/ko not_active IP Right Cessation
- 2005-04-27 CN CN2005800117870A patent/CN1942473B/zh not_active Expired - Fee Related
- 2005-04-27 WO PCT/JP2005/008034 patent/WO2005105807A1/ja active Application Filing
- 2005-04-27 CA CA2565013A patent/CA2565013C/en not_active Expired - Fee Related
- 2005-04-27 PT PT05737233T patent/PT1741716E/pt unknown
- 2005-04-27 MX MXPA06012588A patent/MXPA06012588A/es active IP Right Grant
-
2006
- 2006-10-29 IL IL178918A patent/IL178918A/en not_active IP Right Cessation
-
2007
- 2007-02-15 HK HK07101873.3A patent/HK1094582A1/xx not_active IP Right Cessation
-
2008
- 2008-09-25 US US12/238,070 patent/US7678919B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0912578A (ja) * | 1995-04-28 | 1997-01-14 | Dai Ichi Seiyaku Co Ltd | 五環性化合物 |
WO2001027115A1 (fr) * | 1999-10-15 | 2001-04-19 | Daiichi Pharmaceutical Co., Ltd. | Composes pentacycliques au taxane |
JP2002332287A (ja) * | 2001-03-07 | 2002-11-22 | Dai Ichi Seiyaku Co Ltd | 五環性タキサン化合物およびその製造方法 |
Non-Patent Citations (4)
Title |
---|
BISCHOFBERGER N. ET AL: "Synthesis of analogs of 1,3-dehydroxyacetone phosphate and glyceraldehyde 3-phosphate for use in studies in fructose-1,6-diphosphate aldolase.", JOURNAL OF ORGANIC CHEMISTRY., vol. 53, no. 15, 1988, pages 3457 - 3465, XP000994868 * |
BOLSTER M. ET AL: "The synthesis of Ambox-like compounds starting from (+)-larixol. Part 2.", TETRAHEDRON., vol. 57, no. 39, 2001, pages 8369 - 8379, XP004305842 * |
BOLSTER M.G. ET AL: "The synthesis of Ambrox-like compounds starting from(+)-larixol.", TETRAHEDRON., vol. 57, no. 26, 2001, pages 5663 - 5679, XP004247105 * |
TAKEDA Y. ET AL: "New highly active taxoids from 9 beta-Dihydrobaccatin-9,10-acetals.", BIOORGANIC & MEDICINAL CHEMISTRY., vol. 11, no. 20, 2003, pages 4431 - 4447, XP002990390 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100056770A1 (en) * | 2006-10-10 | 2010-03-04 | Axt Steven D | Preparation of nucleosides ribofuranosyl pyrimidines |
US8912321B2 (en) * | 2006-10-10 | 2014-12-16 | Gilead Pharmasset Llc | Preparation of nucleosides ribofuranosyl pyrimidines |
JP2013530234A (ja) * | 2010-06-30 | 2013-07-25 | ジェンタ インコーポレイテッド | テセタキセルおよび関連化合物ならびに対応する合成中間体の調製 |
US9434740B2 (en) | 2010-06-30 | 2016-09-06 | Odonate Therapeutics, Llc | Taxane compounds, compositions and methods |
Also Published As
Publication number | Publication date |
---|---|
US20070167630A1 (en) | 2007-07-19 |
CA2565013A1 (en) | 2005-11-10 |
ATE526332T1 (de) | 2011-10-15 |
IL178918A (en) | 2011-06-30 |
JP4800205B2 (ja) | 2011-10-26 |
PT1741716E (pt) | 2011-12-21 |
KR20070026553A (ko) | 2007-03-08 |
EP1741716B1 (en) | 2011-09-28 |
DK1741716T3 (da) | 2011-11-28 |
US7456302B2 (en) | 2008-11-25 |
KR101186475B1 (ko) | 2012-09-27 |
EP1741716A4 (en) | 2009-03-04 |
EP1741716B8 (en) | 2012-02-22 |
JPWO2005105807A1 (ja) | 2008-03-13 |
US7678919B2 (en) | 2010-03-16 |
US20090030209A1 (en) | 2009-01-29 |
CN1942473B (zh) | 2011-02-02 |
CN1942473A (zh) | 2007-04-04 |
EP1741716A1 (en) | 2007-01-10 |
CA2565013C (en) | 2013-01-08 |
MXPA06012588A (es) | 2007-01-31 |
HK1094582A1 (en) | 2007-04-04 |
IL178918A0 (en) | 2007-03-08 |
ES2371947T3 (es) | 2012-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019043724A1 (en) | PROCESSES FOR THE PREPARATION OF (S) -2- (2- (BENZOFURAN-6-CARBONYL) -5,7-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBOXAMIDO) -3- (3) - (METHYLSULFONYL) PHENYL) PROPANOIC AND POLYMORPHS THEREOF | |
WO2005105807A1 (ja) | 五環性タキサンの製造方法 | |
CN115298199A (zh) | 环孢菌素衍生物的制备 | |
JP5960130B2 (ja) | テセタキセルおよび関連化合物ならびに対応する合成中間体の調製 | |
KR20030053026A (ko) | 스핑고신의 합성을 위한 제조방법 | |
KR100921036B1 (ko) | 탁산유도체의 제조방법 및 이에 사용되는 중간체 | |
EP1537094B1 (en) | Methods for converting taxane amides to paclitaxel or other taxanes | |
JP3831954B2 (ja) | 4−ヒドロキシ−2−ピロリドンの製法 | |
CN109641863B (zh) | 用于合成卡非佐米的中间体及其药学上可接受的盐的合成 | |
JP2010270145A (ja) | 14位で官能化されたタキサン誘導体及びその製造方法 | |
JP2020530441A (ja) | アザ糖とその中間体の合成 | |
WO2004099136A1 (ja) | ピロリジン誘導体の製造方法 | |
JP4097287B2 (ja) | 2−アザビシクロ[2.2.1]ヘプタン誘導体、それらの調製法およびそれらの用途 | |
JP2002527509A (ja) | 抗腫瘍剤を製造するための立体選択的な方法 | |
KR101003822B1 (ko) | 도세탁셀의 제조방법 및 도세탁셀의 제조를 위한 신규한중간체 | |
JP2019135220A (ja) | L−カルノシン及びその誘導体の製造方法 | |
CN113372325A (zh) | 一种坦西莫司中间体化合物ⅲ | |
WO2003076404A1 (fr) | Thioester d'acide oligolactique en chaine | |
JPWO2003035605A1 (ja) | 新規化合物及びその製造方法 | |
WO2002064623A1 (fr) | Procede de preparation de derives peptidiques | |
JPS59148773A (ja) | γ−ラクトン化合物及びその用途 | |
JP2010215557A (ja) | シクロヘキセンカルボン酸エステル化合物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006512820 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580011787.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2565013 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 178918 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005737233 Country of ref document: EP Ref document number: 2007167630 Country of ref document: US Ref document number: PA/a/2006/012588 Country of ref document: MX Ref document number: 11579140 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067025289 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005737233 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067025289 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 11579140 Country of ref document: US |